The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FDA pilot program that speeds up regulatory review of medicines deemed critical for national security or public health.
The post Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA appeared first on MedCity News.
